Alfred J. Novak - 21 Oct 2022 Form 4 Insider Report for Pasithea Therapeutics Corp. (KTTA)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KTTA	Stock Option (to acquire Common Stock)	Award	$0	+100,000		$0.000000	100,000	21 Oct 2022	Common Stock	100,000	$1.06	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	The Reporting Person was granted 100,000 stock options. The stock options have a ten-year term and vest over two years, subject to Mr. Novak's continued service as a director, one-half vesting on the first anniversary of the grant date, and the remaining 50% vesting on the second anniversary of the grant date.